LONDON, Jan. 29, 2015 /PRNewswire/ -- Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise!. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines.
This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. The therapy class report highlights the future potential of this stream of medicine and the radical way in which diseases could be treated in the next few decades. This new stream of medicine is driven by landmark scientific discoveries and research (Nobel prize in 2012).
In recent years, the translation of research into the clinic has been spearheaded by Rising stars companies (RS). Some of them have come in the limelight because of their technology platform, clinical data, successful IPO, etc. We expect most of these home grown technologies/products developed by the RS/ Research collaborations to fuel the pipeline of large pharma through acquisition or collaboration when the drug is in late stage or approved. The Regenerative medicine Universe is large and new companies are rapidly becoming a part of this universe. . As a result, we have used some filters to select a few names for a detailed coverage in our Outlook this year. Needless to say, that this could just be the tip of the iceberg!
Key Criteria for Our Selection:-
- Uniqueness of the Technology platform and the ability to scale up
- Commercial value in case of positive outcome of the products in the pipeline
- Pipeline and clinical data analysis
- Marketed product and commercial tie up. Robustness of the Management, financial and business model.
Download the full report: https://www.reportbuyer.com/product/2629094/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48